HomeCompareSRLN vs MRK

SRLN vs MRK: Dividend Comparison 2026

SRLN yields 7.73% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SRLN wins by $2.6K in total portfolio value
10 years
SRLN
SRLN
● Live price
7.73%
Share price
$40.14
Annual div
$3.10
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.4K
Annual income
$1,260.76
Full SRLN calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — SRLN vs MRK

📍 SRLN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRLNMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRLN + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRLN pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRLN
Annual income on $10K today (after 15% tax)
$656.84/yr
After 10yr DRIP, annual income (after tax)
$1,071.65/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, SRLN beats the other by $263.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRLN + MRK for your $10,000?

SRLN: 50%MRK: 50%
100% MRK50/50100% SRLN
Portfolio after 10yr
$32.0K
Annual income
$1,105.53/yr
Blended yield
3.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SRLN
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRLN buys
0
MRK buys
0
No recent congressional trades found for SRLN or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRLNMRK
Forward yield7.73%3.25%
Annual dividend / share$3.10$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$33.4K$30.7K
Annual income after 10y$1,260.76$950.29
Total dividends collected$10.2K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SRLN vs MRK ($10,000, DRIP)

YearSRLN PortfolioSRLN Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,473$772.76$11,192$351.54+$281.00SRLN
2$13,104$828.56$12,524$392.70+$580.00SRLN
3$14,906$884.49$14,015$438.65+$891.00SRLN
4$16,890$940.28$15,682$489.96+$1.2KSRLN
5$19,068$995.71$17,547$547.23+$1.5KSRLN
6$21,453$1,050.57$19,632$611.16+$1.8KSRLN
7$24,060$1,104.67$21,963$682.53+$2.1KSRLN
8$26,902$1,157.83$24,571$762.18+$2.3KSRLN
9$29,995$1,209.90$27,486$851.08+$2.5KSRLN
10$33,355$1,260.76$30,745$950.29+$2.6KSRLN

SRLN vs MRK: Complete Analysis 2026

SRLNStock

The State Street Blackstone Senior Loan ETF (SRLN) is an actively managed strategy that seeks to provide current income consistent with the preservation of capital by normally investing at least 80% of its net assets in Senior Loans. For purposes of this 80% test, "Senior Loans" are first lien senior secured floating rate bank loans.In selecting securities for the Fund, the Fund’s sub-adviser, Blackstone Liquid Credit Strategies LLC, seeks to construct a portfolio of loans that it believes is less volatile than the general loan market.In pursuing its investment objective, SRLN seeks to outperform the Morningstar LSTA U.S. Leveraged Loan Index.

Full SRLN Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this SRLN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRLN vs SCHDSRLN vs JEPISRLN vs OSRLN vs KOSRLN vs MAINSRLN vs JNJSRLN vs ABBVSRLN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.